Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Erdafitinib for Sale > Erdafitinib Quality assurance promise Super high-quality white powder
Erdafitinib  Quality assurance promise Super high-quality white powder buy - large image1
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image1
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image2
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image3
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image4
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image5
Erdafitinib  Quality assurance promise Super high-quality white powder buy - image6

Erdafitinib Quality assurance promise Super high-quality white powder

460 Inquiries

Unit Price:

$290/G FOB

Get Latest Price
CAS No.:

1346242-81-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

HK

Brand:

SHENGYUFAN INTERNATIONAL TRADING CO.,LTD.

Packaging:

KIT

Sample Available:

Yes

Price valid (until):

2027-12-31

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
Qualification:
Main Products:

peptide

  • Product Description

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Items Specifications
    Product name Erdafitinib
    CAS NO. 1346242-81-6
    Purity 99%

    We are dedicated to providing high-quality peptides at affordable prices. Our products are produced quickly and safely. Provide samples before regular order. And our products have been spread across Europe, South America, North America, Southeast Asia, Africa and more countries in the world.In order to serve customers well, the company has established special technical department and after-sale service department. We will make careful reply if you get any question.

    Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 1


      Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 2

      • Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 3

    Company Profile

    Shengyufan international trading co.,ltd.is an enterprise mainly in engaged in researching, producing and saling new-born API. Our company is located in Shijiazhuang city,Hebei province.
    We have many years of professional experiences and a professional team of scientists and advanced equipments. Nowadays we formed a large varieties large scale, complete categories and high technology content product chain. Our quality system has been accredited by SGS and our quality center guarantees quality with full documentation control and complete facilities.
    Based on the good quality, pretty competitive price and safe delivery our products are widely exported to many different countries, like Netherlands, Spain, UK, USA and so on. And our products are highly recognized by customers around the world, so we can build long-term cooperative relationship with many pharmaceutical enterprises in the world. We upload the principles of openness and transparency and dedicated to provide efficient and high quality services to every customer. We are sincerely looking forward to establishing a long-term stable and win-win business relationship with every customer.

    Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 4

    FAQ


    1.Q: Are you Trading Company or Manufacturer Factory?A: We have more than 20 years manufacturer experience. our own manufacturing
    bases for some items specially. Also all products have competitive price and quality guarantee.

    2.Q: Can I get some samples?
    A:Yes,we would like to supply samples.

    3.Q:What's your MOQ?
    A:Usually 1 box,we accept sample order.

    4.Q:How to delivery the goods?
    A:EMS/ EUB/ USPS/ UPS/ TNT/ FEDEX/ DHL etc

    5.Q:What's your delivery time.
    A:Usually 1-2 working days after your payment.

    6.What's your advantage?
    1. Best service, high quality and reasonable price 2. It's customers' right to choose the package (EMS, DHL, FedEx, UPS); 3. It's customers' right to choose the packing way for his products from many recent effective packing ways 4. Specials are possible when client's order is big enough, including the discount policy; 5. Our company promise to deliver clients' package to his hands safely, or we'll cover the total loss and reship in time

    Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 5

    —Why Choose us —

    Quality : Above 99% Purity, manufacturer direct supply the products,can supply the certificate of analysis, and can customize any content of powder.

    Transport : Over 99% customs clearance can be guaranteed, the delivery time within 48h and arrival time is 1-2 weeks, Even if the goods are detained, i will resend the goods.

    Service : We offer custom label and custom product services.We keep tracking the shippment until clients well received.We provide you with professional guidance on product use and product customization.

    Price : We do not engagein price wars. Our first quotation may too expensive to you, please don't lose heart. Firstly, our quality can be guaranteed; Secondly, our tranportation efficiency and custome clearance rate can be guaranteed; Thirdly, we will provide you with the highest quality service, in any aspect.

    You get what you pay off, if you have any questions, i will have the answer. Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 6 Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 7 Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 8 Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 9

    Payment method

    Shop High Purity Lyophilized powder vials in stock MT1 CAS NO.  1566590-77-9-Detailed Image 10

    ECHEMI Editorial Reference
    Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
    In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

    Basic Info
    Product Name:

    Erdafitinib

    Other Name:

    1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

    CAS No.:

    1346242-81-6

    Molecular Formula:

    C25H30N6O2

    InChIKeys:

    InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

    Molecular Weight:

    446.54

    Exact Mass:

    446.54

    UNII:

    890E37NHMV

    NCI Thesaurus Code:

    C103273

    ATC Code:

    L - Antineoplastic and immunomodulating agents

    Characteristics
    PSA:

    77.3

    XLogP3:

    3.2

    Density:

    1.2±0.1 g/cm3

    Flash Point:

    354.4±31.5 °C

    Refractive Index:

    1.618

    Water Solubility:

    <1 mg/mL

    Research
    Class:

    Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

    Status:

    Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

    Mechanism:

    Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

    EC50 (Fgfr1 Ic50):

    1.2 nM

    EC50 (Fgfr3 Ic50):

    3.0 nM

    EC50 (Fgfr2 Ic50):

    2.5 nM

    EC50 (Fgfr4 Ic50):

    5.7 nM

    EC50 (Vegfr2 Ic50):

    36.8 nM (approximately 30-fold selectivity vs FGFR1)

    Source:

    Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

    Clinical Development:

    NCT02365597; NCT03390504

    FDA:

    Balversa (approved 2019-04-12)

    References
    ChEMBL:

    CHEMBL3545376

    DrugBank:

    DB12147

    KEGG DRUG:

    D10927

    PubChem:

    PubChem

    Disclaimer:

    Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

    Hazard Identification

    Classification of the substance or mixture

    Acute toxicity - Category 4, Oral

    Skin sensitization, Sub-category 1B

    Serious eye damage, Category 1

    Reproductive toxicity, Category 2

    Specific target organ toxicity – repeated exposure, Category 1

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Danger

    Hazard statement(s)

    H302 Harmful if swallowed

    H317 May cause an allergic skin reaction

    H318 Causes serious eye damage

    H361 Suspected of damaging fertility or the unborn child

    H372 Causes damage to organs through prolonged or repeated exposure

    Precautionary statement(s)
    Prevention

    P264 Wash ... thoroughly after handling.

    P270 Do not eat, drink or smoke when using this product.

    P261 Avoid breathing dust/fume/gas/mist/vapours/spray.

    P272 Contaminated work clothing should not be allowed out of the workplace.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    P203 Obtain, read and follow all safety instructions before use.

    P260 Do not breathe dust/fume/gas/mist/vapours/spray.

    Response

    P301+P317 IF SWALLOWED: Get medical help.

    P330 Rinse mouth.

    P302+P352 IF ON SKIN: Wash with plenty of water/...

    P333+P317 If skin irritation or rash occurs: Get medical help.

    P321 Specific treatment (see ... on this label).

    P362+P364 Take off contaminated clothing and wash it before reuse.

    P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

    P317 Get medical help.

    P318 IF exposed or concerned, get medical advice.

    P319 Get medical help if you feel unwell.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    peptide

    Location:

    Green Home, No. 1, Jianming South Road, Chang'an District, Shijiazhuang City, Hebei Province

    Payment Terms:

    TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

    Total Employees:

    5-10

    Year of Establishment:

    2025

  • Inquiry History
    460 Inquiries
    Country Product Purchase Quantity Date Posted
    Germany

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 25, 2026
    Vietnam

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 18, 2026
    United States

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Jul 26, 2026
    Australia

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Aug 14, 2026
    Poland

    High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib

    1 G Jul 28, 2026
    Canada

    Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

    1 G Sep 15, 2026
    United Kingdom

    Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

    1 MT Sep 4, 2026
    Canada

    Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6

    500 MG Sep 1, 2026
    Canada

    Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6

    500 MG Aug 25, 2026
    United States

    Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder

    1 G Sep 3, 2026
    United States

    Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price

    3 MT Jul 5, 2026
    Australia

    Erdafitinib

    500 MG Sep 16, 2026
    Australia

    Erdafitinib

    1 G Jul 18, 2026
    Germany

    Erdafitinib

    500 MG Jul 28, 2026
    Cyprus

    Erdafitinib

    1 G Jul 22, 2026
    Spain

    Erdafitinib

    1 G Sep 25, 2026
    Bulgaria

    Erdafitinib

    500 MG Jun 18, 2026
    Spain

    Erdafitinib

    1  Sep 14, 2026
    Germany

    Erdafitinib

    5 G Sep 17, 2026
    Switzerland

    1g Erdafitinib raw powder >99% purity

    1 G May 22, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.